Significance of Clinical Factors As Prognostic Indicators for Patients with Peripheral T-cell Non-Hodgkin Lymphoma: A Retrospective Analysis of 252 Cases

Wanzhuo Xie,Keyue Hu,Fan Xu,De Zhou,Weijia Huang,Jingsong He,Jimin Shi,Yi Luo,Jie Zhang,Maofang Lin,Xiujin Ye,Zhen Cai,He Huang
DOI: https://doi.org/10.3892/mco.2013.146
2013-01-01
Molecular and Clinical Oncology
Abstract:The aim of this study was to retrospectively analyze the significance of different clinical factors for predicting the prognosis of patients with peripheral T-cell non-Hodgkin lymphoma (PTCL) with a median follow-up of 23 months. A total of 252 PTCL patients admitted to the First Affiliated Hospital of the School of Medicine of Zhejiang University between 2005 and 2011 were retrospectively reviewed. At a median follow-up of 23 months, the overall survival (OS) rate was 23.8%. Our results revealed that the presence of B symptoms (P<0.001), Eastern Cooperative Oncology Group (ECOG) score ≥2 (P<0.001), bone marrow involvement (BMI) (P<0.001), elevated lactate dehydrogenase (LDH) levels (P<0.001), elevated β2-MG levels (P<0.001), Ann Arbor stages III/IV (P=0.007) and International Prognostic Index (IPI) ≥3 (P=0.001) were poor prognostic factors for OS and intensive chemotherapy achieved a better OS outcome compared to the CHOP treatment. In conclusion, elevated LDH and β2-MG levels, B symptoms, Ann Arbor stages III/IV, BMI, high IPIs and high ECOG scores predict an unfavorable prognosis for PTCL patients. Compared to the conventional CHOP regimen, the intensive chemotherapy treatment may improve the prognosis of PTCL patients.
What problem does this paper attempt to address?